Literature DB >> 22273275

Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ).

Jörn Moock1, Franz Hessel, Diana Ziegeler, Thomas Kubiak, Thomas Kohlmann.   

Abstract

OBJECTIVES: : To develop and psychometrically evaluate a domain-specific questionnaire to assess subtle but clinically relevant differences in treatment experiences and satisfaction over a wide range of currently available insulin therapy regimens. The study focussed on patients with type 2 diabetes mellitus and placed particular attention on the impact of different forms of insulin therapy on diabetes self-management.
METHODS: : The development of the Insulin Treatment Experience Questionnaire (ITEQ) was conducted in three steps: (i) a qualitative phase to generate relevant items and identify relevant domains; (ii) a pilot study to reduce the number of generated items; and (iii) a validation study to assess major psychometric properties of the final ITEQ version.
RESULTS: : The final version of the questionnaire comprised 28 items with the subscales 'leisure activities' (four items), 'psychological barriers' (two items), 'handling' (five items), 'diabetes control' (six items), 'dependence' (five items), 'weight control' (three items), 'sleep' (two items), and one further item assessing general treatment satisfaction. The subscales' internal consistencies (Cronbach's alpha) ranged from 0.52 to 0.83. Motivated by the homogenous structure of inter-scale-correlations (range 0.10-0.46), a summary composite score was calculated (alpha = 0.86). Construct validity showed statistically significant correlations with other scales (ITEQ vs the Problem Areas in Diabetes [PAID] questionnaire total score -0.60, ITEQ vs the Diabetes Treatment Satisfaction Questionnaire [DTSQ] total score 0.52).
CONCLUSION: : The newly developed ITEQ displayed satisfactory to good psychometric properties, thereby allowing the assessment of everyday life experience and treatment satisfaction in patients with insulin-treated type 2 diabetes. Additional research is needed to assess test-retest reliability and sensitivity to change.

Entities:  

Year:  2010        PMID: 22273275     DOI: 10.2165/11319510-000000000-00000

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  19 in total

1.  The cost of diabetes Type II in Europe: the CODE-2 Study.

Authors:  M Massi-Benedetti
Journal:  Diabetologia       Date:  2002-05-24       Impact factor: 10.122

2.  Convergent and discriminant validation by the multitrait-multimethod matrix.

Authors:  D T CAMPBELL; D W FISKE
Journal:  Psychol Bull       Date:  1959-03       Impact factor: 17.737

Review 3.  Quality of life and diabetes.

Authors:  R R Rubin; M Peyrot
Journal:  Diabetes Metab Res Rev       Date:  1999 May-Jun       Impact factor: 4.876

4.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Authors:  R C Turner; H Millns; H A Neil; I M Stratton; S E Manley; D R Matthews; R R Holman
Journal:  BMJ       Date:  1998-03-14

5.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

6.  Assessment of diabetes-related distress.

Authors:  W H Polonsky; B J Anderson; P A Lohrer; G Welch; A M Jacobson; J E Aponte; C E Schwartz
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

7.  Development and validation of the insulin treatment satisfaction questionnaire.

Authors:  Roger T Anderson; Soren E Skovlund; David Marrero; Douglas W Levine; Keith Meadows; Meryl Brod; Rajesh Balkrishnan
Journal:  Clin Ther       Date:  2004-04       Impact factor: 3.393

8.  Maximizing the value of validation findings to better understand treatment satisfaction issues for diabetes.

Authors:  Meryl Brod; Torsten Christensen; Donald Bushnell
Journal:  Qual Life Res       Date:  2007-05-22       Impact factor: 4.147

Review 9.  Economic costs of diabetes in the U.S. In 2007.

Authors: 
Journal:  Diabetes Care       Date:  2008-03       Impact factor: 19.112

Review 10.  Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.

Authors:  D A Revicki; D Osoba; D Fairclough; I Barofsky; R Berzon; N K Leidy; M Rothman
Journal:  Qual Life Res       Date:  2000       Impact factor: 3.440

View more
  4 in total

1.  [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].

Authors:  Ralph Achim Bierwirth; Thomas Kohlmann; Jörn Moock; Rolf Holle; Wolfgang Landgraf
Journal:  Med Klin (Munich)       Date:  2010-12-07

2.  Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial.

Authors:  Norbert Hermanns; Bernd Kulzer; Thomas Kohlmann; Stephan Jacob; Wolfgang Landgraf; Karlheinz Theobald; Thomas Haak
Journal:  Health Qual Life Outcomes       Date:  2015-06-09       Impact factor: 3.186

Review 3.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

4.  Measurement Properties of Patient-Reported Outcome Measures for Diabetes: Systematic Review.

Authors:  Priscilla Jia Ling Wee; Yu Heng Kwan; Dionne Hui Fang Loh; Jie Kie Phang; Troy H Puar; Truls Østbye; Julian Thumboo; Sungwon Yoon; Lian Leng Low
Journal:  J Med Internet Res       Date:  2021-08-13       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.